BMY vs. ABBV
Compare and contrast key facts about Bristol-Myers Squibb Company (BMY) and AbbVie Inc. (ABBV).
Performance
BMY vs. ABBV - Performance Comparison
Loading graphics...
BMY vs. ABBV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 13.77% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
ABBV AbbVie Inc. | -4.05% | 33.08% | 18.86% | -0.23% | 24.01% | 32.43% | 27.72% | 1.47% | -0.96% | 60.07% |
Fundamentals
BMY:
$123.79B
ABBV:
$385.83B
BMY:
$3.46
ABBV:
$2.38
BMY:
17.53
ABBV:
91.23
BMY:
2.57
ABBV:
6.30
BMY:
$48.19B
ABBV:
$61.16B
BMY:
$30.43B
ABBV:
$44.85B
BMY:
$13.82B
ABBV:
$28.29B
Returns By Period
In the year-to-date period, BMY achieves a 13.77% return, which is significantly higher than ABBV's -4.05% return. Over the past 10 years, BMY has underperformed ABBV with an annualized return of 2.72%, while ABBV has yielded a comparatively higher 19.07% annualized return.
BMY
- 1D
- 1.54%
- 1M
- -2.76%
- YTD
- 13.77%
- 6M
- 37.94%
- 1Y
- 4.47%
- 3Y*
- 0.11%
- 5Y*
- 3.12%
- 10Y*
- 2.72%
ABBV
- 1D
- 2.05%
- 1M
- -6.29%
- YTD
- -4.05%
- 6M
- -4.63%
- 1Y
- 7.29%
- 3Y*
- 15.00%
- 5Y*
- 19.40%
- 10Y*
- 19.07%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BMY vs. ABBV — Risk / Return Rank
BMY
ABBV
BMY vs. ABBV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| BMY | ABBV | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.16 | 0.27 | -0.11 |
Sortino ratioReturn per unit of downside risk | 0.43 | 0.54 | -0.11 |
Omega ratioGain probability vs. loss probability | 1.05 | 1.07 | -0.02 |
Calmar ratioReturn relative to maximum drawdown | 0.22 | 0.53 | -0.30 |
Martin ratioReturn relative to average drawdown | 0.35 | 1.17 | -0.82 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| BMY | ABBV | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.16 | 0.27 | -0.11 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.13 | 0.86 | -0.73 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.11 | 0.74 | -0.64 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.35 | 0.74 | -0.39 |
Correlation
The correlation between BMY and ABBV is 0.47, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
BMY vs. ABBV - Dividend Comparison
BMY's dividend yield for the trailing twelve months is around 4.11%, more than ABBV's 3.06% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BMY Bristol-Myers Squibb Company | 4.11% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
ABBV AbbVie Inc. | 3.06% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
Drawdowns
BMY vs. ABBV - Drawdown Comparison
The maximum BMY drawdown since its inception was -72.03%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for BMY and ABBV.
Loading graphics...
Drawdown Indicators
| BMY | ABBV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -72.03% | -45.09% | -26.94% |
Max Drawdown (1Y)Largest decline over 1 year | -25.79% | -16.74% | -9.05% |
Max Drawdown (5Y)Largest decline over 5 years | -47.67% | -21.92% | -25.75% |
Max Drawdown (10Y)Largest decline over 10 years | -47.67% | -45.09% | -2.58% |
Current DrawdownCurrent decline from peak | -13.61% | -9.64% | -3.97% |
Average DrawdownAverage peak-to-trough decline | -22.40% | -10.70% | -11.70% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 17.63% | 8.12% | +9.51% |
Volatility
BMY vs. ABBV - Volatility Comparison
The current volatility for Bristol-Myers Squibb Company (BMY) is 6.67%, while AbbVie Inc. (ABBV) has a volatility of 7.57%. This indicates that BMY experiences smaller price fluctuations and is considered to be less risky than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| BMY | ABBV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.67% | 7.57% | -0.90% |
Volatility (6M)Calculated over the trailing 6-month period | 19.42% | 19.03% | +0.39% |
Volatility (1Y)Calculated over the trailing 1-year period | 28.60% | 27.12% | +1.48% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.66% | 22.61% | +1.05% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.08% | 25.71% | -0.63% |
Financials
BMY vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
BMY vs. ABBV - Profitability Comparison
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a gross profit of 6.24B and revenue of 12.50B. Therefore, the gross margin over that period was 49.9%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a gross profit of 13.96B and revenue of 16.62B. Therefore, the gross margin over that period was 84.0%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported an operating income of 1.47B and revenue of 12.50B, resulting in an operating margin of 11.8%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported an operating income of 5.81B and revenue of 16.62B, resulting in an operating margin of 35.0%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a net income of 1.09B and revenue of 12.50B, resulting in a net margin of 8.7%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AbbVie Inc. reported a net income of 1.82B and revenue of 16.62B, resulting in a net margin of 10.9%.